Sponsor Roll-Up Strategies and Antitrust Risk

The platform-and-add-on model has been a foundational sponsor strategy for two decades. A platform acquisition establishes the operational foundation; a series of subsequent add-ons builds scale, geographic coverage, and adjacent capabilities; and the combined business exits at a multiple expansion that justifies the underlying thesis. The model works in many sectors and has produced strong returns across multiple cycles.

The antitrust risk profile of the model has changed. Federal and state agencies have made clear, in policy statements and in enforcement actions, that the cumulative effect of a sponsor-led acquisition program - even when each individual transaction sits below the HSR reporting threshold - is a relevant antitrust consideration. The agencies have brought matters challenging serial acquisition strategies in healthcare, professional services, and certain consumer categories. The challenges have produced both prospective remedies (commitments to refrain from further acquisitions in defined geographies or sub-segments) and, in a small number of matters, retrospective remedies including divestitures of previously-acquired assets.

For sponsors running active roll-up strategies in 2025, the planning implications are concrete. The antitrust analysis cannot be limited to deal-by-deal HSR-threshold analysis. The platform's cumulative position in defined markets - geographic, product, customer-segment - needs to be tracked with the same rigor as the financial performance. The acquisition pipeline should be evaluated against that cumulative position, with awareness of the markets where additional acquisitions begin to attract scrutiny.

The expanded HSR reporting regime has increased the visibility of serial acquisition activity. The prior-acquisition disclosure requirements give the agencies a more complete picture of a platform's cumulative footprint, and the reformulated narrative requirements give the agencies more context for evaluating each new transaction in light of what has come before. Sponsors should be maintaining a rolling prior-acquisition log, refreshed market-share analysis under multiple plausible market definitions, and a current view of the cumulative competitive position.

The state-level dimension is increasingly important for roll-ups. Healthcare consolidation in particular has drawn substantive state AG attention in multiple states, with both prospective restrictions on further acquisitions and substantive remedy commitments tied to specific service lines or geographic markets. Sponsors with active healthcare platforms should be tracking state-level enforcement priorities alongside federal posture and should engage early with state authorities in jurisdictions of meaningful platform concentration.

Three operational adjustments have become common in well-run roll-up programs. First, the platform-level antitrust analysis is conducted by external counsel with regular refresh cycles - typically annually, with interim refreshes when a meaningful new acquisition is in the pipeline. Second, the diligence on each add-on includes an explicit competitive-overlap analysis tied to the platform's existing footprint, not just to the target's standalone position. Third, the integration playbook includes communications discipline: internal documents discussing the acquisition's strategic rationale should be drafted with awareness that they may be read by an antitrust regulator months or years later.

The structural choices in the platform's organizational documents matter as well. The fund-level documentation governing the sponsor's investment decisions, the platform-level governance, and the integration playbook each interact with the antitrust posture in ways that can support or undermine the platform's defense if a regulator's question arises. Counsel familiar with both transactional and antitrust dimensions of roll-ups should be involved in the documentation architecture from the platform investment forward.

Our practical guidance for sponsors is to plan for the cumulative analysis from the platform investment, refresh the analysis as the program develops, and treat antitrust as an ongoing workstream rather than a deal-specific exercise. The roll-up model remains attractive in many sectors; it requires more antitrust sophistication in 2025 than it required a decade ago, but the additional rigor is manageable. The risk profile is not the strategy; the absence of planning is the risk.

What we are watching

We will return to this topic across the coming quarter. If you are actively negotiating a transaction where these issues are live, we'd welcome a confidential conversation.

Three takeaways

• The market is settling, but the diligence bar is rising.
• Preparation, not posture, is the source of speed.
• The right structure can move price more than another round of negotiation.